Nitromed axes BiDil sales reps

Share this article:

Nitromed announced it plans to lay off a majority of its newly hired BiDil sales force by roughly 70 to 90 employees.

Nitromed doubled its sales force from 30 to 60 specialist reps during the second half of 2007 to boost BiDil. “However, with only modest improvement in sales, management concluded that it cannot sustain BiDil marketing efforts alone,” wrote Friedman, Billings, Ramsey & Co. analyst Robert Uhl in a recent note to investors. Nitromed now expects to file the NDA for BiDil XR with the FDA in 2010. Nitromed has hired an investment bank to explore strategic options, which could lead to sale of the company, Uhl wrote. 
Share this article:
close

Next Article in Features

Email Newsletters

More in Features

Read the complete April 2014 Digital Edition

Read the complete April 2014 Digital Edition

Click the above link to access the complete Digital Edition of the April 2014 issue of MM&M, with all text, charts and pictures.

Antidote: Are e-cigarettes safe?

Antidote: Are e-cigarettes safe?

The pros and cons of e-cigarettes

Combating concept churn

Combating concept churn

There's no cure. But the good news is that prophylaxis is possible.